KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD

By sjmartinez • December 25, 2023

Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2023 Dec 21:S0272-6386(23)00883-1. doi: 10.1053/j.ajkd.2023.09.003. Epub ahead of print. PMID: 38142396.

Tags: Chronic kidney disease, commentary, diabetes, evidence-based recommendation, GLP-1 RAs, guideline, guideline implementation, Nephrology, nephrology best practices, ns-MRAs, Publications, SGLT2 inhibitors

Research Code Sharing in Support of Gold Standard Science

Klonoff DC, Espinoza J, Mader JK, Heinemann L, Cobelli C, Kerr D, Kovatchev B, Najafi B, Prahalad P, Zheng Y, Shao MM, Scheideman AF, DuNova[...]

Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol

Naim MAAZ, Sumida K, Streja E, Thomas F, Davis RL, Kalantar-Zadeh K, Kovesdy CP. Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on[...]

Letter to the Editor re: Valenzuela et al. 2025 STAR working group report on dd-cfDNA validation

Bromberg JS, Bunnapradist S, Demko ZP, Gauthier P. Letter to the Editor re: Valenzuela et al. 2025 STAR working group report on dd-cfDNA validation. Am[...]